Sound Bioventures, a venture capital fund, invests in Theolytics, a UK biotechnology company, to advance THEO-260 in ovarian cancer trials. The funding round raised £19M ($24.5M) with strong international syndicate support. Theolytics aims to bring a potential therapy to ovarian cancer patients, addressing a critical unmet need in the field. Theolytics' lead asset, THEO-260, shows promise in killing cancer cells and cancer-associated fibroblasts, offering hope for patients with limited treatment options. The investment from Sound Bioventures signifies a significant step forward in the fight against cancer.